Search research articles
Contact Us
Filters
Showing results (1-10 of 134) with videos related to
Page
of 14
Sort By:
Pharmacology & Therapeutics
|
July 21, 2006
Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy
Andrew P Levy
The Israel Medical Association Journal : IMAJ
|
May 21, 2004
Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease
Andrew P Levy
Pediatric Endocrinology Reviews : PER
|
January 24, 2006
Angiogenesis--an update
Ariel Roguin, Andrew P Levy
Vascular Health and Risk Management
|
February 27, 2007
In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease
Rabea Asleh, Andrew P Levy
JACC. Cardiovascular Imaging
|
April 23, 2018
Personalized Medicine in the Prevention of Reperfusion Injury?
Andrew P Levy, Erik Schelbert
Antioxidants & Redox Signaling
|
September 23, 2009
Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype
Rabea Asleh, Andrew P Levy
International Journal of Cardiovascular Interventions
|
December 10, 2002
Basic principles of angiogenesis for the interventional cardiologist
Andrew P Levy, Ariel Roguin
Clinical Laboratory
|
March 2, 2006
Haptoglobin phenotypes, which one is better and when?
Burbea Zvi, Andrew P Levy
Current Diabetes Reports
|
March 20, 2012
Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?
Moshe Vardi, Andrew P Levy
Heart Rhythm
|
June 3, 2026
Haptoglobin, Hemolysis, and Renal Vulnerability After Pulsed Field Ablation: The Hemoglobin-Binding Reserve
Andrew P Levy, Rabea Asleh
Page
of 14
Search research articles
Search
Showing results (1-10 of 134) with videos related to
Sort By:
Page
of 14
Pharmacology & Therapeutics
|
July 21, 2006
Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy
Andrew P Levy
The Israel Medical Association Journal : IMAJ
|
May 21, 2004
Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease
Andrew P Levy
Pediatric Endocrinology Reviews : PER
|
January 24, 2006
Angiogenesis--an update
Ariel Roguin, Andrew P Levy
Vascular Health and Risk Management
|
February 27, 2007
In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease
Rabea Asleh, Andrew P Levy
JACC. Cardiovascular Imaging
|
April 23, 2018
Personalized Medicine in the Prevention of Reperfusion Injury?
Andrew P Levy, Erik Schelbert
Antioxidants & Redox Signaling
|
September 23, 2009
Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype
Rabea Asleh, Andrew P Levy
International Journal of Cardiovascular Interventions
|
December 10, 2002
Basic principles of angiogenesis for the interventional cardiologist
Andrew P Levy, Ariel Roguin
Clinical Laboratory
|
March 2, 2006
Haptoglobin phenotypes, which one is better and when?
Burbea Zvi, Andrew P Levy
Current Diabetes Reports
|
March 20, 2012
Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?
Moshe Vardi, Andrew P Levy
Heart Rhythm
|
June 3, 2026
Haptoglobin, Hemolysis, and Renal Vulnerability After Pulsed Field Ablation: The Hemoglobin-Binding Reserve
Andrew P Levy, Rabea Asleh
Page
of 14